Home » Topics » Ocular, BioWorld Science

Ocular, BioWorld Science
RSS

Alcon files second portion of Retaane rolling NDA

July 6, 2004

Isis earns milestone for Macugen NDA filing

July 1, 2004

Statins a potential therapeutic option in glaucoma

June 29, 2004

Istalol NDA for glaucoma approved

June 9, 2004

Tosufloxacin tosilate eye drops submitted for Japanese approval

June 9, 2004

SnET2 NDA accepted for priority review

June 4, 2004

Proposed financing at InSite to advance AzaSite development

June 4, 2004

Allergan and Kyorin sign Japanese agreement for Alphagan franchise

June 2, 2004

FDA sets date to discuss Macugen NDA

June 1, 2004

Allergan presents new prostaglandin analogues with utility as ocular hypotensive agents

May 28, 2004

Popular Stories

Today's news in brief
BioWorld
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
New mechanism of action identified for QC-6352
BioWorld Science
QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...